Professor Klaus Okkenhaug

University of Cambridge

University departments
Department of Pathology

Position: Professor
Personal home page:

PubMed journal articles - click here

Professor Klaus Okkenhaug is pleased to consider applications from prospective PhD students.

Research description

Phosphoinositide 3-kinases (PI3Ks) are enzymes that act downstream of tyrosine kinase signalling and generate second messenger signalling molecules that can regulate cell survival, metabolism, growth, proliferation, differentiation and migration. We are investigating the regulation of PI3Ks in lymphocytes using genetic and pharmacological approaches. We also investigate how manipulation of PI3K signalling influences different kinds of immune responses including against cancer. Results from these investigations help provide rationale for the use of PI3K inhibitors in therapeutic settings. Indeed, the PI3Kdelta inhibitor idelalisib is already approved for the treatment of certain B cell malignancies (CLL, SLL, FL) and PI3Kdelta inhibitors are also being trialled as immunotherapeutic agents in solid cancer.

Research Programme
Haematological Malignancies
Secondary Programme
Pancreatic Cancer
Methods and technologies
Confocal microscopy
Fluorescence microscopy
Gene expression profiling
In vivo modelling
Tumour type interests
cell signalling
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Okkenhaug K. 2013.
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells.
Annual Review of Immunology 31: 675-704

Ali K et al. 2014.
Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer.
Nature 510: 407-11

Burger JA, Okkenhaug K. 2014.
Haematological cancer: idelalisib-targeting PI3Kdelta in patients with B-cell malignancies.
Nat Rev Clin Oncol 11: 184-6

Okkenhaug K, Graupera M, Vanhaesebroeck B.
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Cancer Discov. 2016 O6(10):1090-1105.